Pacific Biosciences Of California (PACB) FCF Margin Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | 884.00 |
| 2 | Stryker | 126.77 Bn | 123.30 Bn | 4.50 Bn | 534.00 |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | -310.00 |
| 4 | Boston Scientific | 73.18 Bn | 72.64 Bn | 3.85 Bn | 919.00 |
| 5 | Edwards Lifesciences | 52.05 Bn | 47.80 Bn | 1.35 Bn | 3,472.00 |
| 6 | Dexcom | 34.35 Bn | 32.40 Bn | 830.00 Mn | -97.00 |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | 413.00 |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | -63.00 |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 60.00 |
| 10 | Pacific Biosciences Of California | 388.32 Mn | 151.45 Mn | 12.64 Mn | -270.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -270.00 |
| Mar 31, 2026 | 12,459.00 |
| Dec 31, 2025 | 19,471.00 |
| Sep 30, 2025 | 15,967.00 |
| Jun 30, 2025 | 10,683.00 |
| Mar 31, 2025 | 12,688.00 |
| Dec 31, 2024 | 1,366.00 |
| Jun 30, 2024 | -9,833.00 |
| Mar 31, 2024 | -12,394.00 |
| Dec 31, 2023 | -4,929.00 |
| Sep 30, 2023 | -2,240.00 |
| Jun 30, 2023 | 4,866.00 |
| Mar 31, 2023 | -73,540.00 |
| Dec 31, 2022 | -17,376.00 |
| Sep 30, 2022 | -12,557.00 |
| Jun 30, 2022 | -10,828.00 |
| Mar 31, 2022 | -8,746.00 |
| Dec 31, 2021 | 160.00 |
| Jun 30, 2021 | 1,701.00 |
| Mar 31, 2021 | 1,767.00 |